Review: Adaptive Radiation Therapy for Head and Neck Cancer

Brandon M. Godinich; Cem Dede; Clifton D. Fuller; Ergys Subashi; Grace Murley; Laia Humbert-Vidan; Lucas McCullum; Natalie A. West; Parshawn Gerafian; Qusai Alakayleh

REVIEW 4 major objections 6 minor 228 references

Review: Adaptive Radiation Therapy for Head and Neck Cancer

T0 review · 4 major / 6 minor · reviewed 2026-08-06 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

Pith's one-line read The review argues that adaptive radiotherapy for head and neck cancer is entering an imaging-biomarker era, and that a standardized validation framework—beginning with a Delphi consensus study—is needed before these tools can guide…

desk verdict A useful narrative review and trial compilation whose forward-looking 'must adapt now' framing outruns the evidence it itself cites; worth serious peer review. read the letter →

arxiv 2508.00651 v1 pith:76MIY37G submitted 2025-08-01 physics.med-ph

Lucas McCullum , Sonali J. Joshi , Brandon M. Godinich , Parshawn Gerafian , Rishabh Gaur , Qusai Alakayleh , Ergys Subashi , Renjie He

show 8 more authors

Samuel L. Mulder Zaphanlene Kaffey Grace Murley Natalie A. West Saleh Ramezani Cem Dede Laia Humbert-Vidan Clifton D. Fuller

This is my paper

classification physics.med-ph

keywords adaptiveradiationtherapyheadandneckcancerimagingbiomarkersMR-LinacmagneticresonancefingerprintingbiomarkerstandardizationclinicaltranslationPET-guidedradiotherapy

verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

Adaptive radiation therapy for head and neck cancer alters the treatment plan as the tumor and normal anatomy change during the course of radiotherapy. This review argues that the field is entering a new era in which imaging biomarkers—such as measures of water diffusion, blood flow, and tissue relaxation—can tell clinicians when and how to adapt, and new devices such as MRI-guided linear accelerators and PET-guided delivery systems can act on that information in near real time. The paper's central claim is that these biomarkers and technologies are not yet ready for routine use because they lack standardized definitions, measurement protocols, and validation pathways, and it proposes a Delphi consensus study to build a framework called IB-IDEAL for harmonized development and testing. At stake is whether adaptation becomes biology-driven rather than schedule-driven, and whether the field can generate the evidence needed to show that adaptation actually improves patient outcomes.

What carries the argument

The load-bearing proposal is a structured validation framework for imaging biomarkers: a Delphi consensus study intended to produce the IB-IDEAL initiative, a harmonized development pathway for imaging biomarkers specific to radiation oncology. The paper also surveys the technical enablers—MRI-guided linear accelerators, PET-guided radiotherapy delivery, AI-based auto-segmentation, synthetic CT generation, and multiparametric MRI methods such as diffusion-weighted imaging, dynamic contrast enhancement, and MR fingerprinting—and treats them as components that this framework would standardize and validate. The argument is carried by the claim that these components are individually promising but collectively uncoordinated, and that a consensus-based evaluation pathway is the missing link.

What would settle it

A prospective multicenter trial in which mid-treatment imaging biomarkers (for example, a measured change in apparent diffusion coefficient at week three) are used to trigger replanning, compared against standard weekly replanning, would settle the claim: if the biomarker-guided arm shows no improvement in locoregional control or patient-reported toxicity, or if the biomarker cannot be measured reproducibly across centers with the recommended protocols, the paper's central recommendation loses its empirical basis.

Watch

Extended reading notes

Core claim

On the paper's own terms, adaptive radiation therapy for head and neck cancer is nearing a transition: technical platforms now exist that can both measure biological change and act on it, but the field lacks the shared standards to turn that capability into reliable clinical decisions. The review's central claim is that imaging biomarkers—apparent diffusion coefficient, dynamic contrast enhancement, tissue relaxometry, oxygen-sensitive signals, and MR fingerprinting—can inform when and how to adapt treatment, and that new delivery systems such as MRI-guided linear accelerators and PET-guided radiotherapy should be used to respond to those signals in near real time. Because the current evidence base contains only one completed phase III randomized trial of ART, which did not show significant differences in primary endpoints, the paper does not argue for one optimal implementation; instead it argues for coordinated standardization, starting with a Delphi consensus study that would produce a harmonized development pathway for imaging biomarkers (proposed as IB-IDEAL). The goal is to close the translational gap between research tools and routine patient care, and to make adaptation a biology-driven rather than schedule-driven intervention.

Load-bearing premise

The recommendations depend on the assumption that imaging biomarkers such as apparent diffusion coefficient, dynamic contrast enhancement, and MR fingerprinting can be validated and translated into adaptive-treatment decisions; this is not established by the cited evidence, which includes only a single completed phase III randomized trial of ART and it showed no significant difference in primary endpoints.

Editorial extensions

If this is right

If imaging biomarkers are validated, adaptive plans can be triggered by measured tumor response rather than by fixed weekly schedules, potentially concentrating dose where it is needed.
A harmonized framework like the proposed Delphi-based IB-IDEAL would give the field shared terminology and reporting standards, making independent studies comparable and enabling credible multi-center trials.
MR-guided and PET-guided treatment systems could act on biomarker signals in near real time, shifting adaptation from offline replanning to online, even intra-fraction, adjustment.
NTCP-aware adaptation, in which replanning is triggered by predicted normal-tissue complication risks, would combine with biomarker information to personalize both dose and timing.
If the framework is adopted, the evidence base can move beyond the single completed phase III trial (which did not show a significant difference in primary endpoints) toward trials in which the right patients receive the right adaptation at the right time.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

A natural extension is that the inconclusive first phase III trial might be reinterpreted: if biomarkers identify patients whose anatomy is changing in a way that adaptation would help, the benefit of ART may be real but hidden in unselected populations, and a biomarker-stratified trial would test this directly.
A biological-extension inference is that the proposed consensus process would need to specify not only how biomarkers are reported but also how they gain regulatory clearance, a step the review touches on but does not resolve.
A testable near-term extension would be to use the reported week-three ADC change (with an area under the curve near 0.83 for predicting local recurrence) as the trigger for a prospective adaptive trial, with validation thresholds fixed before enrollment.
If imaging biomarkers fail external validation, the fallback may be purely dosimetric adaptation using NTCP thresholds, which is already supported by retrospective data; the biomarker program would then remain a research tool rather than a clinical driver.

Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Desk Editor's Note

read the letter

Colleague—

This is a narrative review, not a research paper, so judge it as a synthesis. It does a genuinely useful thing: it pulls together the clinical trial landscape for ART in head and neck cancer (the big Table 1 is the most valuable single item), and it gives a readable tour of where the technology stands—Halcyon, Ethos, MR-Linac, RefleXion—and where imaging biomarkers (ADC, DCE, CEST, BOLD, IVIM, MRF, SyntheticMR) are in their maturity. The proposal for an 'IB-IDEAL' framework via Delphi is sensible and modestly framed as a starting point.

The soft spots are real but not disqualifying. Table 1 contains transcription-level errors that a careful referee would catch (e.g., enrollment numbers like '41 Dec 2009,' '100 Aug 2011' that are obviously corrupted). The forward-looking claim in the abstract and conclusion—that biomarker integration 'must be addressed now' for patient impact—outruns the evidence the review itself cites. The only completed phase III trial (ARTIX) found no significant differences in primary or secondary endpoints except parotid excretory function. Much of the ADC/DWI evidence is from preprints or small single-center studies. BOLD is described as 'inconsistent' in the review's own text; IVIM on MR-Linac showed low correlations. So the stress-test concern holds: the evidence supports a research agenda, not a directive for immediate clinical integration. The review is not dishonest about this—it acknowledges many of these limitations in passing—but the framing pushes past what the cited literature establishes. Also, the claim that RSNA is shifting away from QIBA is stated without citation; if true it needs a source.

On balance, this is a competent, useful review with a clear organizational purpose. It would benefit from a referee who fixes the table, softens the 'must be addressed now' language, and requires citations for the RSNA/QIBA claim. Self-citation appears but is not a defect here; the self-cited work (R-IDEAL, MR-Linac consortium papers) is directly on point.

Who is this for? Clinicians and physicists looking for a one-stop orientation to ART technologies and the biomarker evidence base. It deserves a serious peer review, not a desk reject, because the trial compilation alone is a resource the field will use.

Recommendation: send it to review, but expect heavy revision on the evidentiary claims and table accuracy. I would not rely on its conclusions about biomarker readiness without checking the primary sources.

Referee Report

4 major / 6 minor

Summary. The manuscript is a narrative review of adaptive radiation therapy (ART) for head and neck cancer (HNC), covering current IGRT platforms (Halcyon, CT-on-Rails, Ethos, MR-Linac), AI-based contouring, emerging PET-guided and MR-based imaging biomarkers (DWI/ADC, DCE, CEST, T1rho, BOLD, ASL/IVIM, SyntheticMR, MRF), and decision-support concepts such as NTCP-aware ART, Markov decision processes, and digital twins. The authors argue that ART for HNC is entering a new era in which imaging biomarkers and new technologies should be integrated into clinical workflows, and they recommend a structured consensus framework (a Delphi study and an 'IB-IDEAL' initiative) to standardize biomarker development and validation in radiation oncology.

Significance. If its forward-looking claims are appropriately tempered, this review would be a useful synthesis for medical physicists, radiation oncologists, and trialists planning ART biomarker studies. Its strengths are breadth and currency: it gathers recent device-specific experience, summarizes quantitative MRI techniques relevant to HNC, and clearly identifies the gap between technical availability of imaging biomarkers and their validated clinical integration. The paper also gives appropriate attention to quality assurance, clinical trial frameworks (R-IDEAL, DECIDE-AI, QIBA), and the need for interdisciplinary collaboration. The main weakness is that the review's central recommendation is stated more strongly than the evidence it cites supports, and several presentation issues (notably in Table 1) undermine its reliability as a reference summary.

major comments (4)

[§1 and §5] The central claim that imaging biomarkers 'must be addressed now' for ART patient impact (§1) and the call for an 'IB-IDEAL' consensus framework (§5) are not supported by the evidence the review itself presents. The only completed phase III ART RCT (ARTIX, ref 10) reported no significant differences in primary or secondary endpoints except parotid excretory function, and the biomarker evidence is dominated by small single-center, retrospective, or preprint studies (e.g., refs 102-104, 158-160). The 'prospective validation' of ADC in ref 102 is a preprint, BOLD results are described as 'inconsistent' (§4.2), and IVIM on the MR-Linac showed 'low correlations' (§4.3). Please reframe the conclusion as a research and standardization agenda, with explicit statements about evidence maturity, rather than as a directive for clinical adoption of these biomarkers.
[Table 1] Table 1 contains multiple impossible entries in the 'Enrollment Start Date' column, such as '41 Dec 2009', '74 Sep 2010', '100 Aug 2011', '0 Nov 2015', '472 May 2018', and '0 Dec 2024'. These appear to result from merging enrollment numbers or other fields with the start date. Since Table 1 is a central reference summary of the trial landscape, please re-extract each row from ClinicalTrials.gov and correct the column, and verify trial phase and status labels against the source records (e.g., NCT01124409 is listed as Phase 3).
[§3.2] The motion statistics quoted for the upper airway of HNC patients (motion greater than 5 mm and 10 mm seen in 13% and 4% of intrafraction imaging time) are attributed to ref 96, which is a study of esophageal motion, not head-and-neck upper-airway motion. This mis-citation weakens the case for real-time motion monitoring on the MR-Linac. Please either replace the citation with HNC-specific cine MRI data (e.g., refs 97-98) or rephrase the claim to reflect the actual study population.
[§5] The statement that 'organizations like RSNA shift their focus, including a move away from QIBA initiatives' is asserted without a citation, and it is part of the rationale for proposing the new IB-IDEAL framework. Please add a verifiable source for this claim or qualify it as the authors' opinion. In addition, if IB-IDEAL is intended as a concrete proposal, the review should define its scope, stakeholders, and relationship to existing frameworks (R-IDEAL, DECIDE-AI, QIBA) rather than naming it only in the final paragraph.

minor comments (6)

[§2.2.2] The sentence 'Although cone-beam CT (CBCT) is commonly used for patient setup due to its integration into radiotherapy systems and the ability to perform imaging directly in the treatment position...' is duplicated; please delete the repeated sentence.
[§2.2.4] The text 'developed by Elekta and Phillips' should be 'developed by Elekta and Philips'.
[§4.3] The word 'redout' should be 'readout' in the description of arterial spin labeling.
[§4.4.2] The phrase 'On of the most exciting recent expansions' should be 'One of the most exciting recent expansions'.
[Table 1] The row for NCT05996432 lists the primary outcome as 'Imaging biomarkers' but the summary says 'Use of MRI for identifying radioresistence'; 'radioresistence' should be 'radioresistance'.
[References] Several references to the Journal of Magnetic Resonance Imaging are listed with the journal title 'Magnetic Resonance Imaging' (e.g., refs 159-160), which is a different journal; please standardize the journal names across the reference list.

Circularity Check

0 steps flagged · score 0.0 of 10

No significant circularity: the paper is a narrative review that makes no derived predictions; its self-citations are evidentiary rather than load-bearing.

full rationale

This manuscript is a narrative review of adaptive radiation therapy (ART) for head and neck cancer, not a derivation of new quantitative results. It contains no fitted parameters, no equations whose outputs are defined by their inputs, and no prediction that is statistically forced by a prior fit. The paper's central call for imaging-biomarker validation and for a structured consensus framework ('IB-IDEAL') is presented explicitly as a proposal and a research need rather than as a result derived from data. Its statements about biomarker performance are literature summaries, and where those summaries rely on the authors' own prior work or preprints, the citations point to external studies (e.g., refs 102, 103, 196-198, 213) that are not outputs of the present review and are not used to define the review's conclusions. The self-citation in the proposed framework lineage (R-IDEAL, ref 32, with a co-author overlap) is used as an example of an existing evaluation framework, not as an authority that forecloses alternatives. The paper even disclaims providing a single correct answer in its abstract and conclusion. Thus no step in the paper reduces by construction to its own inputs, and the review's forward-looking recommendations, however contestable on evidence-maturity grounds, are not circular.

Assumptions & free parameters 0 free parameters · 3 assumptions · 1 invented entities

The review itself is a synthesis and introduces no new equations or fitted values. The assumptions listed are domain level premises the forward looking arguments depend on: biomarker translatability, the accuracy of the cited evidence, and an asserted institutional trend (RSNA/QIBA) that is stated without citation.

assumptions (3)

domain assumption Imaging biomarkers (ADC, DCE, MRF, etc.) will eventually be validated and improve ART decision making.
The review's future directions sections assume these biomarkers can be translated into clinical practice, despite only one completed phase III ART trial showing no significant primary endpoint differences.
domain assumption RSNA is moving away from QIBA initiatives, creating a leadership gap in imaging biomarkers for radiation oncology.
Stated in Section 5 without a supporting citation; this is an asserted institutional trend that underpins the proposal for an alternative framework.
domain assumption The cited literature is accurately interpreted and representative of the field.
A review's conclusions rest on faithful reading of cited trials and device studies; errors in Table 1 suggest some data handling is unreliable.

invented entities (1)

IB-IDEAL initiative
purpose: A proposed harmonized development pathway for imaging biomarkers in radiation oncology.
Proposed in the conclusion as a future initiative; no operationalization or validation is presented.

how reviews work

0 comments

Cite this review

Pith. "Pith review of Review: Adaptive Radiation Therapy for Head and Neck Cancer." pith.science (2026). https://pith.science/paper/76MIY37G

@misc{pith2026250800651,
  author       = {Pith},
  title        = {Pith review of: Review: Adaptive Radiation Therapy for Head and Neck Cancer},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/76MIY37G}},
  note         = {Machine review of arXiv:2508.00651}
}

read the original abstract

The future of ART in head and neck cancer is just beginning. Novel technologies have pushed the boundary of what is possible in terms of techniques to identify biomarkers for adaptation as well as innovative devices specialized to respond to these adaptations, sometimes in real-time. Important interdisciplinary steps must be taken moving forward to ensure the safe deployment of these new techniques, such as rigorous quality assurance evaluations from medical physicists, clinical trials from physicians, and comprehensive testing from vendors prior to release. In summary, we aimed not to provide a single correct answer for the optimal implementation of ART in the era of imaging biomarkers, but to encourage the field to collaborate and bring each idea discussed here together to overcome current barriers and deliver the best treatment possible to the patient.

Discussion (0). Sign in to comment.

Reference graph

Works this paper leans on

228 extracted references · 170 canonical work pages

[1]

Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist’s point of view

Nuyts S, Bollen H, Eisbruch A, et al. Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist’s point of view. Cancer Medicine. 2024;13(8):e7192. doi:10.1002/cam4.7192

work page doi:10.1002/cam4.7192 2024
[2]

Clinical and dosimetric impact of adaptive intensity-modulated radiotherapy in locally advanced head-and- neck cancer

Maheshwari G, Dhanawat A, Kumar HS, Sharma N, Jakhar SL. Clinical and dosimetric impact of adaptive intensity-modulated radiotherapy in locally advanced head-and- neck cancer. Journal of Cancer Research and Therapeutics. 2020;16(3):600-604. doi:10.4103/jcrt.JCRT_928_19

work page doi:10.4103/jcrt.jcrt_928_19 2020
[3]

In silico evaluation and feasibility of near margin- less head and neck daily adaptive radiotherapy

Dohopolski M, Visak J, Choi B, et al. In silico evaluation and feasibility of near margin- less head and neck daily adaptive radiotherapy. Radiotherapy and Oncology. 2024;197:110178. doi:10.1016/j.radonc.2024.110178

arXiv 2024
[4]

In Silico Analysis of Adjuvant Head and Neck Online Adaptive Radiation Therapy

All S, Zhong X, Choi B, et al. In Silico Analysis of Adjuvant Head and Neck Online Adaptive Radiation Therapy. Advances in Radiation Oncology. 2024;9(1):101319. doi:10.1016/j.adro.2023.101319

arXiv 2024
[5]

Replanning During Intensity Modulated Radiation Therapy Improved Quality of Life in Patients With Nasopharyngeal Carcinoma

Yang H, Hu W, Wang W, Chen P, Ding W, Luo W. Replanning During Intensity Modulated Radiation Therapy Improved Quality of Life in Patients With Nasopharyngeal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 2013;85(1):e47-e54. doi:10.1016/j.ijrobp.2012.09.033

work page doi:10.1016/j.ijrobp.2012.09.033 2013
[6]

The Levels of Evidence and Their Role in Evidence- Based Medicine: Plastic and Reconstructive Surgery

Burns PB, Rohrich RJ, Chung KC. The Levels of Evidence and Their Role in Evidence- Based Medicine: Plastic and Reconstructive Surgery. 2011;128(1):305-310. doi:10.1097/PRS.0b013e318219c171

work page doi:10.1097/prs.0b013e318219c171 2011
[7]

Disease Control and Late Toxicity in Adaptive Dose Painting by Numbers Versus Nonadaptive Radiation Therapy for Head and Neck Cancer: A Randomized Controlled Phase 2 Trial

De Bruycker A, De Neve W, Daisne JF, et al. Disease Control and Late Toxicity in Adaptive Dose Painting by Numbers Versus Nonadaptive Radiation Therapy for Head and Neck Cancer: A Randomized Controlled Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 2024;120(2):516-527. doi:10.1016/j.ijrobp.2024.01.012 30

work page doi:10.1016/j.ijrobp.2024.01.012 2024
[8]

Adaptive Dose Painting by Numbers for Head-and-Neck Cancer

Duprez F, De Neve W, De Gersem W, Coghe M, Madani I. Adaptive Dose Painting by Numbers for Head-and-Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 2011;80(4):1045-1055. doi:10.1016/j.ijrobp.2010.03.028

work page doi:10.1016/j.ijrobp.2010.03.028 2011

Show all 228 references

[9]

Ghosh Laskar S, Sinha S, Kumar A, et al. Reducing Salivary Toxicity with Adaptive Radiotherapy (ReSTART): A Randomized Controlled Trial Comparing Conventional IMRT to Adaptive IMRT in Head and Neck Squamous Cell Carcinomas. Clinical Oncology. 2024;36(6):353-361. doi:10.1016/j....

2024 doi
[10]

Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial

Castelli J, Thariat J, Benezery K, et al. Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023;9(8):1056. doi:10.1001/jamaoncol.2023.1352

2023
[11]

Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer

Madani I, Duprez F, Boterberg T, et al. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. Radiotherapy and Oncology. 2011;101(3):351-355. doi:10.1016/j.radonc.2011.06.020

2011 doi
[12]

Ding Y, Mohamed ASR, Yang J, et al. Prospective observer and software-based assessment of magnetic resonance imaging quality in head and neck cancer: Should standard positioning and immobilization be required for radiation therapy applications? Practical Radiation Oncology. 20...

2015 doi
[13]

Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence

Mowery YM, Vergalasova I, Rushing CN, et al. Early 18F-FDG-PET Response During Radiation Therapy for HPV-Related Oropharyngeal Cancer May Predict Disease Recurrence. Int J Radiat Oncol Biol Phys. 2020;108(4):969-976. doi:10.1016/j.ijrobp.2020.08.029

2020 doi
[14]

Heukelom J, Hamming O, Bartelink H, et al. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer. 2013;13:84. doi:10.1186/1471-2407-13-84

2013 doi
[15]

A Phase II Trial Evaluating Rapid Mid-Treatment Nodal Shrinkage to Select for Adaptive Deescalation in p16+ Oropharyngeal Cancer Patients Undergoing Definitive Chemoradiation

Kim JK, Tam M, Karp JM, et al. A Phase II Trial Evaluating Rapid Mid-Treatment Nodal Shrinkage to Select for Adaptive Deescalation in p16+ Oropharyngeal Cancer Patients Undergoing Definitive Chemoradiation. International Journal of Radiation Oncology*Biology*Physics. 2023;117(...

2023 doi
[16]

Adaptive FDG-PET/CT guided dose escalation in head and neck squamous cell carcinoma: Late toxicity and oncologic outcomes (The ADMIRE study)

Al-Mamgani A, Kessels R, Gouw ZAR, et al. Adaptive FDG-PET/CT guided dose escalation in head and neck squamous cell carcinoma: Late toxicity and oncologic outcomes (The ADMIRE study). Clin Transl Radiat Oncol. 2023;43:100676. doi:10.1016/j.ctro.2023.100676 31

2023
[17]

Longitudinal assessment of diffusion-weighted imaging during magnetic resonance-guided radiotherapy in head and neck cancer

Boeke S, Habrich J, Kübler S, et al. Longitudinal assessment of diffusion-weighted imaging during magnetic resonance-guided radiotherapy in head and neck cancer. Radiat Oncol. 2025;20(1):15. doi:10.1186/s13014-025-02589-9

2025 doi
[18]

MR-Guided Adaptive Radiotherapy for Head and Neck Cancer: Prospective Evaluation of Migration and Anatomical Changes of the Major Salivary Glands

van Timmeren JE, Chamberlain M, Bogowicz M, et al. MR-Guided Adaptive Radiotherapy for Head and Neck Cancer: Prospective Evaluation of Migration and Anatomical Changes of the Major Salivary Glands. Cancers (Basel). 2021;13(21):5404. doi:10.3390/cancers13215404

2021 doi
[19]

Sakanaka K, Ishida Y, Fujii K, et al. Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single- institution Phase I Study. Clin Oncol...

2021 doi
[20]

Interim 18F-FDG-PET based response-adaptive dose escalation of proton therapy for head and neck cancer: a treatment planning feasibility study

Garrido-Hernandez G, Henjum H, Winter RM, et al. Interim 18F-FDG-PET based response-adaptive dose escalation of proton therapy for head and neck cancer: a treatment planning feasibility study. Physica Medica. 2024;123:103404. doi:10.1016/j.ejmp.2024.103404

2024
[21]

Differential Response in Quantitative MRI Parameters Detected in Head and Neck Cancer Patients Treated with Concurrent Immunotherapy during Hypo-Fractionated MR-gRT

Bonate R, Paulson ES, Frei A, et al. Differential Response in Quantitative MRI Parameters Detected in Head and Neck Cancer Patients Treated with Concurrent Immunotherapy during Hypo-Fractionated MR-gRT. International Journal of Radiation Oncology*Biology*Physics. 2023;117(2, S...

2023 doi
[22]

Accessed June 10, 2025

Impact of circulating tumor human papillomavirus DNA kinetics on disease outcomes in HPV‐associated oropharyngeal cancer - Jhawar - 2025 - International Journal of Cancer - Wiley Online Library. Accessed June 10, 2025. https://onlinelibrary.wiley.com/doi/10.1002/ijc.35291

2025 doi
[23]

Cone-beam computed tomography- based online adaptive radiotherapy of esophageal cancer in the neoadjuvant setting: Dosimetric analysis, toxicity and treatment response

Bachmann N, Ahmadsei M, Hürlimann M, et al. Cone-beam computed tomography- based online adaptive radiotherapy of esophageal cancer in the neoadjuvant setting: Dosimetric analysis, toxicity and treatment response. Radiotherapy and Oncology. 2025;209:110981. doi:10.1016/j.radonc...

2025
[24]

A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol

Courtney PT, L Santoso M, Savjani RR, et al. A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol. BMC Cancer. 2024;24(1):1564. doi:10.1186/s12885-02...

2024 doi
[25]

Feasibility of Adaptive Radiation Therapy for Human-Papilloma Virus-Positive Oropharyngeal Cancer Patients Using MR- Guided RT

Jethanandani A, Freedman LM, Kubicek GJ, et al. Feasibility of Adaptive Radiation Therapy for Human-Papilloma Virus-Positive Oropharyngeal Cancer Patients Using MR- Guided RT. International Journal of Radiation Oncology, Biology, Physics. 2024;118(5):e15. doi:10.1016/j.ijrobp....

2024 doi
[26]

BEST (Biomarkers, EndpointS, and Other Tools) Resource

FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and Other Tools) Resource. Food and Drug Administration (US); 2016. Accessed December 29, 2024. http://www.ncbi.nlm.nih.gov/books/NBK326791/

2016
[27]

Imaging biomarker roadmap for cancer studies

O’Connor JPB, Aboagye EO, Adams JE, et al. Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017;14(3):169-186. doi:10.1038/nrclinonc.2016.162

2017 doi
[28]

Van Houdt PJ, Saeed H, Thorwarth D, et al. Integration of quantitative imaging biomarkers in clinical trials for MR-guided radiotherapy: Conceptual guidance for multicentre studies from the MR-Linac Consortium Imaging Biomarker Working Group. European Journal of Cancer. 2021;1...

2021 doi
[29]

The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker

Boss MA, Malyarenko D, Partridge S, et al. The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker. Goh V, ed. Radiology. 2024;313(1):e233055. doi:10.1148/radiol.233055

2024 doi
[30]

Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE- AI

Vasey B, Nagendran M, Campbell B, et al. Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE- AI. BMJ. Published online May 18, 2022:e070904. doi:10.1136/bmj-2022-070904

2022 doi
[31]

DECIDE-AI: a new reporting guideline and its relevance to artificial intelligence studies in radiology

Vasey B, Novak A, Ather S, Ibrahim M, McCulloch P. DECIDE-AI: a new reporting guideline and its relevance to artificial intelligence studies in radiology. Clinical Radiology. 2023;78(2):130-136. doi:10.1016/j.crad.2022.09.131

2023 doi
[32]

R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology

Verkooijen HM, Kerkmeijer LGW, Fuller CD, et al. R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. Front Oncol. 2017;7. doi:10.3389/fonc.2017.00059

2017
[33]

The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping

Zwanenburg A, Vallières M, Abdalah MA, et al. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. 2020;295(2):328-338. doi:10.1148/radiol.2020191145

2020 doi
[34]

Bahig H, Yuan Y, Mohamed ASR, et al. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a- 2b/Bayesian phase II trial. Clin Transl Radiat Oncol. 2...

2018 doi
[35]

Metrology Standards for Quantitative Imaging Biomarkers

Sullivan DC, Obuchowski NA, Kessler LG, et al. Metrology Standards for Quantitative Imaging Biomarkers. Radiology. 2015;277(3):813-825. doi:10.1148/radiol.2015142202

2015 doi
[36]

Image Guided Radiation Therapy (IGRT) Technologies for Radiation Therapy Localization and Delivery

De Los Santos J, Popple R, Agazaryan N, et al. Image Guided Radiation Therapy (IGRT) Technologies for Radiation Therapy Localization and Delivery. International Journal of Radiation Oncology*Biology*Physics. 2013;87(1):33-45. doi:10.1016/j.ijrobp.2013.02.021 33

2013 doi
[37]

Quality and Safety Considerations in Image Guided Radiation Therapy: An ASTRO Safety White Paper Update

Qi XS, Albuquerque K, Bailey S, et al. Quality and Safety Considerations in Image Guided Radiation Therapy: An ASTRO Safety White Paper Update. Practical Radiation Oncology. 2023;13(2):97-111. doi:10.1016/j.prro.2022.09.004

2023 doi
[38]

Image guided radiotherapy moving towards real time adaptive radiotherapy; global positioning system for radiotherapy? Technical Innovations & Patient Support in Radiation Oncology

McNair H, Buijs M. Image guided radiotherapy moving towards real time adaptive radiotherapy; global positioning system for radiotherapy? Technical Innovations & Patient Support in Radiation Oncology. 2019;12:1-2. doi:10.1016/j.tipsro.2019.10.006

2019 doi
[39]

Head and Neck Cancer Adaptive Radiation Therapy (ART): Conceptual Considerations for the Informed Clinician

Heukelom J, Fuller CD. Head and Neck Cancer Adaptive Radiation Therapy (ART): Conceptual Considerations for the Informed Clinician. Seminars in Radiation Oncology. 2019;29(3):258-273. doi:10.1016/j.semradonc.2019.02.008

2019 doi
[40]

Two novel stereotactic radiotherapy methods for locally advanced, previously irradiated head and neck cancers patients

Pokhrel D, Misa J, McCarthy S, Yang ES. Two novel stereotactic radiotherapy methods for locally advanced, previously irradiated head and neck cancers patients. Med Dosim. 2024;49(2):114-120. doi:10.1016/j.meddos.2023.09.003

2024 doi
[41]

Dosimetric performance evaluation of the Halcyon treatment platform for stereotactic radiotherapy: A pooled study

Huang Y, Liu Z. Dosimetric performance evaluation of the Halcyon treatment platform for stereotactic radiotherapy: A pooled study. Medicine. 2023;102(36):e34933. doi:10.1097/MD.0000000000034933

2023 doi
[42]

Dosimetric comparison between VMAT plans using the fast-rotating O-ring linac with dual-layer stacked MLC and helical tomotherapy for nasopharyngeal carcinoma

Ju SG, Ahn YC, Kim YB, et al. Dosimetric comparison between VMAT plans using the fast-rotating O-ring linac with dual-layer stacked MLC and helical tomotherapy for nasopharyngeal carcinoma. Radiat Oncol. 2022;17(1):155. doi:10.1186/s13014-022- 02124-0

2022 doi
[43]

Evaluation of auto-planning in IMRT and VMAT for head and neck cancer

Ouyang Z, Liu Shen Z, Murray E, et al. Evaluation of auto-planning in IMRT and VMAT for head and neck cancer. J Appl Clin Med Phys. 2019;20(7):39-47. doi:10.1002/acm2.12652

2019 doi
[44]

Characterization of the HalcyonTM multileaf collimator system

Lim TY, Dragojević I, Hoffman D, Flores-Martinez E, Kim GY. Characterization of the HalcyonTM multileaf collimator system. J Appl Clin Med Phys. 2019;20(4):106-114. doi:10.1002/acm2.12568

2019 doi
[45]

Benchmarking halcyon ring delivery system for hypofractionated breast radiotherapy: Validation and clinical implementation of the fast‐forward trial

Pokhrel D, Smith M, Volk A, Bernard ME. Benchmarking halcyon ring delivery system for hypofractionated breast radiotherapy: Validation and clinical implementation of the fast‐forward trial. J Applied Clin Med Phys. 2023;24(9):e14047. doi:10.1002/acm2.14047

2023 doi
[46]

Treatment time of image-guided radiotherapy with a Halcyon 2.0 system

Hermida-López M, García-Relancio D, Comino-Muriano M, et al. Treatment time of image-guided radiotherapy with a Halcyon 2.0 system. Journal of Medical Imaging and Radiation Sciences. 2023;54(1):117-122. doi:10.1016/j.jmir.2022.12.002

2023 doi
[47]

A Simulated Dosimetric Study of Contribution to Radiotherapy Accuracy by Fractional Image Guidance Protocol of Halcyon System

Wang H, Huang Y, Hu Q, et al. A Simulated Dosimetric Study of Contribution to Radiotherapy Accuracy by Fractional Image Guidance Protocol of Halcyon System. Front Oncol. 2021;10:543147. doi:10.3389/fonc.2020.543147 34

2021
[48]

CT-on-Rails Versus In-Room CBCT for Online Daily Adaptive Proton Therapy of Head-and-Neck Cancers

Nesteruk KP, Bobić M, Lalonde A, Winey BA, Lomax AJ, Paganetti H. CT-on-Rails Versus In-Room CBCT for Online Daily Adaptive Proton Therapy of Head-and-Neck Cancers. Cancers. 2021;13(23):5991. doi:10.3390/cancers13235991

2021 doi
[49]

In-room CT techniques for image-guided radiation therapy

Ma CMC, Paskalev K. In-room CT techniques for image-guided radiation therapy. Med Dosim. 2006;31(1):30-39. doi:10.1016/j.meddos.2005.12.010

2006 doi
[50]

Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system

Barker JL, Garden AS, Ang KK, et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. International Journal of Radiation Oncology*Biology*Physics. 2004;59(4)...

2004 doi
[51]

Applications of linac-mounted kilovoltage Cone-beam Computed Tomography in modern radiation therapy: A review

Srinivasan K, Mohammadi M, Shepherd J. Applications of linac-mounted kilovoltage Cone-beam Computed Tomography in modern radiation therapy: A review. Pol J Radiol. 2014;79:181-193. doi:10.12659/PJR.890745

2014 doi
[52]

Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial

Schwartz DL, Garden AS, Thomas J, et al. Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial. Int J Radiat Oncol Biol Phys. 2012;83(3):986-993. doi:10.1016/j.ijrobp.2011.08.017

2012 doi
[53]

Personalized medicine: From diagnostic to adaptive

Braig ZV. Personalized medicine: From diagnostic to adaptive. Biomedical Journal. 2022;45(1):132-142. doi:10.1016/j.bj.2019.05.004

2022 doi
[54]

Review of cone beam computed tomography based online adaptive radiotherapy: current trend and future direction

Liu H, Schaal D, Curry H, et al. Review of cone beam computed tomography based online adaptive radiotherapy: current trend and future direction. Radiat Oncol. 2023;18(1):144. doi:10.1186/s13014-023-02340-2

2023 doi
[55]

Investigating the feasibility of using Ethos generated treatment plans for head and neck cancer patients

El-qmache A, McLellan J. Investigating the feasibility of using Ethos generated treatment plans for head and neck cancer patients. Technical Innovations & Patient Support in Radiation Oncology. 2023;27:100216. doi:10.1016/j.tipsro.2023.100216

2023
[56]

Evaluation of Ethos intelligent optimization engine for left locally advanced breast cancer

Prunaretty J, Lopez L, Cabaillé M, et al. Evaluation of Ethos intelligent optimization engine for left locally advanced breast cancer. Front Oncol. 2024;14:1399978. doi:10.3389/fonc.2024.1399978

2024
[57]

Technical feasibility of novel immunostimulatory low‐dose radiation for polymetastatic disease with CBCT‐based online adaptive and conventional approaches

Nasser N, Perez BA, Penagaricano JA, et al. Technical feasibility of novel immunostimulatory low‐dose radiation for polymetastatic disease with CBCT‐based online adaptive and conventional approaches. J Applied Clin Med Phys. 2024;25(6):e14303. doi:10.1002/acm2.14303

2024 doi
[58]

Varian ethos online adaptive radiotherapy for prostate cancer: Early results of contouring accuracy, treatment plan quality, and treatment time

Byrne M, Archibald‐Heeren B, Hu Y, et al. Varian ethos online adaptive radiotherapy for prostate cancer: Early results of contouring accuracy, treatment plan quality, and treatment time. J Applied Clin Med Phys. 2022;23(1):e13479. doi:10.1002/acm2.13479 35

2022 doi
[59]

Feasibility of Conebeam CT-based online adaptive radiotherapy for neoadjuvant treatment of rectal cancer

De Jong R, Visser J, Van Wieringen N, Wiersma J, Geijsen D, Bel A. Feasibility of Conebeam CT-based online adaptive radiotherapy for neoadjuvant treatment of rectal cancer. Radiat Oncol. 2021;16(1):136. doi:10.1186/s13014-021-01866-7

2021 doi
[60]

Feasibility study of adaptive radiotherapy with Ethos for breast cancer

Galand A, Prunaretty J, Mir N, et al. Feasibility study of adaptive radiotherapy with Ethos for breast cancer. Front Oncol. 2023;13:1274082. doi:10.3389/fonc.2023.1274082

2023
[61]

A head and neck treatment planning strategy for a CBCT‐guided ring‐gantry online adaptive radiotherapy system

Nasser N, Yang GQ, Koo J, et al. A head and neck treatment planning strategy for a CBCT‐guided ring‐gantry online adaptive radiotherapy system. J Applied Clin Med Phys. 2023;24(12):e14134. doi:10.1002/acm2.14134

2023 doi
[62]

Initial Evaluation of a Novel Cone-Beam CT-Based Semi-Automated Online Adaptive Radiotherapy System for Head and Neck Cancer Treatment – A Timing and Automation Quality Study

Yoon SW, Lin H, Alonso-Basanta M, et al. Initial Evaluation of a Novel Cone-Beam CT-Based Semi-Automated Online Adaptive Radiotherapy System for Head and Neck Cancer Treatment – A Timing and Automation Quality Study. Cureus. Published online August 11, 2020. doi:10.7759/cureus.9660

2020 doi
[63]

Early Experience of Online Adaptive Radiation Therapy for Definitive Radiation of Patients With Head and Neck Cancer

Avkshtol V, Meng B, Shen C, et al. Early Experience of Online Adaptive Radiation Therapy for Definitive Radiation of Patients With Head and Neck Cancer. Advances in Radiation Oncology. 2023;8(5):101256. doi:10.1016/j.adro.2023.101256

2023
[64]

Prospects for online adaptive radiation therapy (ART) for head and neck cancer

Guberina M, Guberina N, Hoffmann C, et al. Prospects for online adaptive radiation therapy (ART) for head and neck cancer. Radiat Oncol. 2024;19(1):4. doi:10.1186/s13014-023-02390-6

2024 doi
[65]

MRI-LINAC: A transformative technology in radiation oncology

Ng J, Gregucci F, Pennell RT, et al. MRI-LINAC: A transformative technology in radiation oncology. Front Oncol. 2023;13:1117874. doi:10.3389/fonc.2023.1117874

2023
[66]

Clinical application of MR-Linac in tumor radiotherapy: a systematic review

Liu X, Li Z, Yin Y. Clinical application of MR-Linac in tumor radiotherapy: a systematic review. Radiat Oncol. 2023;18(1):52. doi:10.1186/s13014-023-02221-8

2023 doi
[67]

Adaptive radiotherapy: The Elekta Unity MR-linac concept

Winkel D, Bol GH, Kroon PS, et al. Adaptive radiotherapy: The Elekta Unity MR-linac concept. Clinical and Translational Radiation Oncology. 2019;18:54-59. doi:10.1016/j.ctro.2019.04.001

2019 doi
[68]

Evaluation of Unity 1.5 T MR‐linac plan quality in patients with prostate cancer

Tanaka S, Kadoya N, Ishizawa M, et al. Evaluation of Unity 1.5 T MR‐linac plan quality in patients with prostate cancer. J Applied Clin Med Phys. 2023;24(12):e14122. doi:10.1002/acm2.14122

2023 doi
[69]

Evaluation of MRI‐only based online adaptive radiotherapy of abdominal region on MR‐ linac

Nousiainen K, Santurio GV, Lundahl N, Cronholm R, Siversson C, Edmund JM. Evaluation of MRI‐only based online adaptive radiotherapy of abdominal region on MR‐ linac. J Applied Clin Med Phys. 2023;24(3):e13838. doi:10.1002/acm2.13838

2023 doi
[70]

MR‐linac is the best modality for lung SBRT

Godley A, Zheng D, Rong Y. MR‐linac is the best modality for lung SBRT. J Applied Clin Med Phys. 2019;20(6):7-11. doi:10.1002/acm2.12615 36

2019 doi
[71]

The Use of MR-Guided Radiation Therapy for Head and Neck Cancer and Recommended Reporting Guidance

McDonald BA, Dal Bello R, Fuller CD, Balermpas P. The Use of MR-Guided Radiation Therapy for Head and Neck Cancer and Recommended Reporting Guidance. Seminars in Radiation Oncology. 2024;34(1):69-83. doi:10.1016/j.semradonc.2023.10.003

2024 doi
[72]

Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians

Hall WA, Paulson E, Li XA, et al. Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians. CA A Cancer J Clinicians. 2022;72(1):34-56. doi:10.3322/caac.21707

2022 doi
[73]

Dose accumulation for MR-guided adaptive radiotherapy: From practical considerations to state-of-the-art clinical implementation

McDonald BA, Zachiu C, Christodouleas J, et al. Dose accumulation for MR-guided adaptive radiotherapy: From practical considerations to state-of-the-art clinical implementation. Front Oncol. 2023;12:1086258. doi:10.3389/fonc.2022.1086258

2023
[74]

A survey on deep learning in medical image analysis

Litjens G, Kooi T, Bejnordi BE, et al. A survey on deep learning in medical image analysis. Medical Image Analysis. 2017;42:60-88. doi:10.1016/j.media.2017.07.005

2017 doi
[75]

Deep Learning in Medical Image Analysis

Shen D, Wu G, Suk HI. Deep Learning in Medical Image Analysis. Annu Rev Biomed Eng. 2017;19:221-248. doi:10.1146/annurev-bioeng-071516-044442

2017 doi
[76]

UNet++: A Nested U-Net Architecture for Medical Image Segmentation

Zhou Z, Siddiquee MMR, Tajbakhsh N, Liang J. UNet++: A Nested U-Net Architecture for Medical Image Segmentation. Deep Learn Med Image Anal Multimodal Learn Clin Decis Support (2018). 2018;11045:3-11. doi:10.1007/978-3-030-00889-5_1

2018 doi
[77]

Dermatologist-level classification of skin cancer with deep neural networks

Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115-118. doi:10.1038/nature21056

2017 doi
[78]

The role of artificial intelligence in radiotherapy clinical practice

Landry G, Kurz C, Traverso A. The role of artificial intelligence in radiotherapy clinical practice. BJR|Open. 2023;5(1):20230030. doi:10.1259/bjro.20230030

2023 doi
[79]

Automated Contouring and Planning in Radiation Therapy: What Is ‘Clinically Acceptable’? Diagnostics

Baroudi H, Brock KK, Cao W, et al. Automated Contouring and Planning in Radiation Therapy: What Is ‘Clinically Acceptable’? Diagnostics. 2023;13(4):667. doi:10.3390/diagnostics13040667

2023 doi
[80]

Artificial Intelligence Uncertainty Quantification in Radiotherapy Applications - A Scoping Review

Wahid KA, Kaffey ZY, Farris DP, et al. Artificial Intelligence Uncertainty Quantification in Radiotherapy Applications - A Scoping Review. Published online May 13, 2024. doi:10.1101/2024.05.13.24307226

2024 doi
[81]

Embracing imperfect datasets: A review of deep learning solutions for medical image segmentation

Tajbakhsh N, Jeyaseelan L, Li Q, Chiang JN, Wu Z, Ding X. Embracing imperfect datasets: A review of deep learning solutions for medical image segmentation. Medical Image Analysis. 2020;63:101693. doi:10.1016/j.media.2020.101693

2020
[82]

The technical design and concept of a PET/CT linac for biology-guided radiotherapy

Oderinde OM, Shirvani SM, Olcott PD, Kuduvalli G, Mazin S, Larkin D. The technical design and concept of a PET/CT linac for biology-guided radiotherapy. Clinical and Translational Radiation Oncology. 2021;29:106-112. doi:10.1016/j.ctro.2021.04.003 37

2021 doi
[83]

Treatment planning system commissioning of the first clinical biology‐guided radiotherapy machine

Simiele E, Capaldi D, Breitkreutz D, et al. Treatment planning system commissioning of the first clinical biology‐guided radiotherapy machine. J Applied Clin Med Phys. 2022;23(8):e13638. doi:10.1002/acm2.13638

2022 doi
[84]

Commissioning of a novel PET‐Linac for biology‐guided radiotherapy (BgRT)

Surucu M, Ashraf MR, Romero IO, et al. Commissioning of a novel PET‐Linac for biology‐guided radiotherapy (BgRT). Medical Physics. 2024;51(6):4389-4401. doi:10.1002/mp.17114

2024 doi
[85]

Demonstration of real‐time positron emission tomography biology‐guided radiotherapy delivery to targets

Oderinde OM, Narayanan M, Olcott P, et al. Demonstration of real‐time positron emission tomography biology‐guided radiotherapy delivery to targets. Medical Physics. 2024;51(8):5672-5681. doi:10.1002/mp.16999

2024 doi
[86]

Image-mode performance characterisation of a positron emission tomography subsystem designed for Biology-guided radiotherapy (BgRT)

Hu Z, Bieniosek M, Ferri V, et al. Image-mode performance characterisation of a positron emission tomography subsystem designed for Biology-guided radiotherapy (BgRT). The British Journal of Radiology. 2023;96(1141):20220387. doi:10.1259/bjr.20220387

2023 doi
[87]

Beam commissioning of the first clinical biology‐guided radiotherapy system

Han B, Capaldi D, Kovalchuk N, et al. Beam commissioning of the first clinical biology‐guided radiotherapy system. J Applied Clin Med Phys. 2022;23(6):e13607. doi:10.1002/acm2.13607

2022 doi
[88]

Comparative evaluation of treatment plan quality for a prototype biology-guided radiotherapy system in the treatment of nasopharyngeal carcinoma

Han C, Da Silva AJ, Liang J, et al. Comparative evaluation of treatment plan quality for a prototype biology-guided radiotherapy system in the treatment of nasopharyngeal carcinoma. Medical Dosimetry. 2021;46(2):171-178. doi:10.1016/j.meddos.2020.11.002

2021 doi
[89]

A detailed process map for clinical workflow of a new biology‐guided radiotherapy (BgRT) machine

Hwang M, Lalonde R, Huq MS. A detailed process map for clinical workflow of a new biology‐guided radiotherapy (BgRT) machine. J Applied Clin Med Phys. 2022;23(6):e13606. doi:10.1002/acm2.13606

2022 doi
[90]

IMRT and SBRT Treatment Planning Study for the First Clinical Biology-Guided Radiotherapy System

Pham D, Simiele E, Breitkreutz D, et al. IMRT and SBRT Treatment Planning Study for the First Clinical Biology-Guided Radiotherapy System. Technol Cancer Res Treat. 2022;21:153303382211002. doi:10.1177/15330338221100231

2022 doi
[91]

First-Year Experience of Stereotactic Body Radiation Therapy/Intensity Modulated Radiation Therapy Treatment Using a Novel Biology-Guided Radiation Therapy Machine

Shi M, Simiele E, Han B, et al. First-Year Experience of Stereotactic Body Radiation Therapy/Intensity Modulated Radiation Therapy Treatment Using a Novel Biology-Guided Radiation Therapy Machine. Advances in Radiation Oncology. 2024;9(1):101300. doi:10.1016/j.adro.2023.101300

2024
[92]

89Zr-panitumumab Combined With 18F- FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma

Lee YJ, Van Den Berg NS, Duan H, et al. 89Zr-panitumumab Combined With 18F- FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 2022;28(20):4425-4434. doi:10.1158/1078-0432.CCR-22- 0094 38

2022 doi
[93]

[68Ga]-DOTATATE PET/MRI in the diagnosis and management of recurrent head and neck paraganglioma with spinal metastasis

Kim SH, Roytman M, Kamen E, et al. [68Ga]-DOTATATE PET/MRI in the diagnosis and management of recurrent head and neck paraganglioma with spinal metastasis. Clinical Imaging. 2021;79:314-318. doi:10.1016/j.clinimag.2021.07.028

2021 doi
[94]

Real-time motion monitoring using orthogonal cine MRI during MR-guided adaptive radiation therapy for abdominal tumors on 1.5T MR- Linac

Jassar H, Tai A, Chen X, et al. Real-time motion monitoring using orthogonal cine MRI during MR-guided adaptive radiation therapy for abdominal tumors on 1.5T MR- Linac. Med Phys. 2023;50(5):3103-3116. doi:10.1002/mp.16342

2023 doi
[95]

Gating and intrafraction drift correction on a 1.5 T MR-Linac: Clinical dosimetric benefits for upper abdominal tumors

Grimbergen G, Hackett SL, Van Ommen F, et al. Gating and intrafraction drift correction on a 1.5 T MR-Linac: Clinical dosimetric benefits for upper abdominal tumors. Radiotherapy and Oncology. 2023;189:109932. doi:10.1016/j.radonc.2023.109932

2023
[96]

RA, Feigenberg SJ, Konski AA

Cohen RJ, Paskalev K, Litwin S, Price Jr. RA, Feigenberg SJ, Konski AA. Original article: Esophageal motion during radiotherapy: quantification and margin implications: Esophageal motion during radiotherapy. Diseases of the Esophagus. 2010;23(6):473-

2010
[97]

Internal margin assessment using cine MRI analysis of deglutition in head and neck cancer radiotherapy

Paulson ES, Bradley JA, Wang D, Ahunbay EE, Schultz C, Li XA. Internal margin assessment using cine MRI analysis of deglutition in head and neck cancer radiotherapy. Medical Physics. 2011;38(4):1740-1747. doi:10.1118/1.3560418

2011 doi
[98]

Dynamic MRI Analysis of Tumor and Organ Motion During Rest and Deglutition and Margin Assessment for Radiotherapy of Head-and-Neck Cancer

Bradley JA, Paulson ES, Ahunbay E, Schultz C, Li XA, Wang D. Dynamic MRI Analysis of Tumor and Organ Motion During Rest and Deglutition and Margin Assessment for Radiotherapy of Head-and-Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 2011;81(5):e803-...

2011 doi
[99]

Li H, Chen HC, Dolly S, et al. An integrated model-driven method for in-treatment upper airway motion tracking using cine MRI in head and neck radiation therapy: In- treatment upper airway motion tracking using cine MRI. Med Phys. 2016;43(8Part1):4700-4710. doi:10.1118/1.4955118

2016 doi
[100]

Diffusion weighted imaging: Technique and applications

Baliyan V, Das CJ, Sharma R, Gupta AK. Diffusion weighted imaging: Technique and applications. WJR. 2016;8(9):785. doi:10.4329/wjr.v8.i9.785

2016 doi
[101]

Diffusion-weighted imaging and apparent diffusion coefficient mapping of head and neck lymph node metastasis: a systematic review

Belfiore MP, Nardone V, D’Onofrio I, et al. Diffusion-weighted imaging and apparent diffusion coefficient mapping of head and neck lymph node metastasis: a systematic review. Exploration of Targeted Anti-tumor Therapy. Published online December 13, 2022:734-745. doi:10.37349/e...

2022
[102]

Joint Head and Neck Radiotherapy-MRI Development Cooperative, Mohamed ASR, Abusaif A, et al. Prospective validation of diffusion-weighted MRI as a biomarker of tumor response and oncologic outcomes in head and neck cancer: Results from an observational biomarker pre-qualificat...

2022 doi
[103]

McDonald BA, Salzillo T, Mulder S, et al. In Vivo and Phantom Repeatability of Diffusion-Weighted MRI Sequences on 1.5T MRI-Linear Accelerator (MR-Linac) and MR Simulator Devices for Head and Neck Cancers: Results from a Prospective R-IDEAL Stage 2a Evaluation of Tumor and Nor...

2022 doi
[104]

McDonald BA, Salzillo T, Mulder S, et al. Prospective evaluation of in vivo and phantom repeatability and reproducibility of diffusion-weighted MRI sequences on 1.5 T MRI-linear accelerator (MR-Linac) and MR simulator devices for head and neck cancers. Radiotherapy and Oncolog...

2023
[105]

El-Habashy DM, Wahid KA, He R, et al. Longitudinal diffusion and volumetric kinetics of head and neck cancer magnetic resonance on a 1.5 T MR-linear accelerator hybrid system: A prospective R-IDEAL stage 2a imaging biomarker characterization/pre- qualification study. Clinical ...

2023
[106]

Joint Head and Neck Radiation Therapy-MRI Development Cooperative, MR-Linac Consortium Head and Neck Tumor Site Group, El-Habashy DM, et al. Longitudinal diffusion and volumetric kinetics of head and neck cancer magnetic resonance on a 1.5T MR-Linear accelerator hybrid system:...

2023 doi
[107]

Weekly Intra-Treatment Diffusion Weighted Imaging Dataset for Head and Neck Cancer Patients Undergoing MR-linac Treatment

El-Habashy DM, Wahid KA, He R, et al. Weekly Intra-Treatment Diffusion Weighted Imaging Dataset for Head and Neck Cancer Patients Undergoing MR-linac Treatment. Published online August 20, 2023. doi:10.1101/2023.08.18.23294280

2023 doi
[108]

Dataset of weekly intra-treatment diffusion weighted imaging in head and neck cancer patients treated with MR-Linac

El-Habashy DM, Wahid KA, He R, et al. Dataset of weekly intra-treatment diffusion weighted imaging in head and neck cancer patients treated with MR-Linac. Sci Data. 2024;11(1):487. doi:10.1038/s41597-024-03217-z

2024 doi
[109]

ADC measurements on the Unity MR-linac – A recommendation on behalf of the Elekta Unity MR-linac consortium

Kooreman ES, Van Houdt PJ, Keesman R, et al. ADC measurements on the Unity MR-linac – A recommendation on behalf of the Elekta Unity MR-linac consortium. Radiotherapy and Oncology. 2020;153:106-113. doi:10.1016/j.radonc.2020.09.046

2020 doi
[110]

Tolerance levels of CT number to electron density table for photon beam in radiotherapy treatment planning system

Nakao M, Ozawa S, Yamada K, et al. Tolerance levels of CT number to electron density table for photon beam in radiotherapy treatment planning system. J Applied Clin Med Phys. 2018;19(1):271-275. doi:10.1002/acm2.12226

2018 doi
[111]

Influence of different factors on registration error in a 1.5 T MR-guided linac

Yin P, Yu G, Hou C, et al. Influence of different factors on registration error in a 1.5 T MR-guided linac. Phys Med Biol. 2023;68(10):10NT02. doi:10.1088/1361-6560/accef9 40

2023 doi
[112]

Toward Magnetic Resonance–Only Simulation: Segmentation of Bone in MR for Radiation Therapy Verification of the Head

Yu H, Caldwell C, Balogh J, Mah K. Toward Magnetic Resonance–Only Simulation: Segmentation of Bone in MR for Radiation Therapy Verification of the Head. International Journal of Radiation Oncology*Biology*Physics. 2014;89(3):649-657. doi:10.1016/j.ijrobp.2014.03.028

2014 doi
[113]

Multiatlas approach with local registration goodness weighting for MRI-based electron density mapping of head and neck anatomy

Farjam R, Tyagi N, Veeraraghavan H, et al. Multiatlas approach with local registration goodness weighting for MRI-based electron density mapping of head and neck anatomy. Med Phys. 2017;44(7):3706-3717. doi:10.1002/mp.12303

2017 doi
[114]

Shape constrained fully convolutional DenseNet with adversarial training for multiorgan segmentation on head and neck CT and low‐field MR images

Tong N, Gou S, Yang S, Cao M, Sheng K. Shape constrained fully convolutional DenseNet with adversarial training for multiorgan segmentation on head and neck CT and low‐field MR images. Medical Physics. 2019;46(6):2669-2682. doi:10.1002/mp.13553

2019 doi
[115]

Dosimetric evaluation of synthetic CT for head and neck radiotherapy generated by a patch‐based three‐dimensional convolutional neural network

Dinkla AM, Florkow MC, Maspero M, et al. Dosimetric evaluation of synthetic CT for head and neck radiotherapy generated by a patch‐based three‐dimensional convolutional neural network. Medical Physics. 2019;46(9):4095-4104. doi:10.1002/mp.13663

2019 doi
[116]

Patch‐based generative adversarial neural network models for head and neck MR‐only planning

Klages P, Benslimane I, Riyahi S, et al. Patch‐based generative adversarial neural network models for head and neck MR‐only planning. Medical Physics. 2020;47(2):626-

2020
[117]

Generation of synthetic megavoltage CT for MRI‐only radiotherapy treatment planning using a 3D deep convolutional neural network

Scholey JE, Rajagopal A, Vasquez EG, Sudhyadhom A, Larson PEZ. Generation of synthetic megavoltage CT for MRI‐only radiotherapy treatment planning using a 3D deep convolutional neural network. Medical Physics. 2022;49(10):6622-6634. doi:10.1002/mp.15876

2022 doi
[118]

Compensation cycle consistent generative adversarial networks (Comp‐GAN) for synthetic CT generation from MR scans with truncated anatomy

Zhao Y, Wang H, Yu C, et al. Compensation cycle consistent generative adversarial networks (Comp‐GAN) for synthetic CT generation from MR scans with truncated anatomy. Medical Physics. 2023;50(7):4399-4414. doi:10.1002/mp.16246

2023 doi
[119]

SC-GAN: Structure-completion generative adversarial network for synthetic CT generation from MR images with truncated anatomy

Chen X, Zhao Y, Court LE, et al. SC-GAN: Structure-completion generative adversarial network for synthetic CT generation from MR images with truncated anatomy. Computerized Medical Imaging and Graphics. 2024;113:102353. doi:10.1016/j.compmedimag.2024.102353

2024
[120]

Multisequence MR‐generated sCT is promising for HNC MR‐only RT: A comprehensive evaluation of previously developed sCT generation networks

Qi M, Li Y, Wu A, Lu X, Zhou L, Song T. Multisequence MR‐generated sCT is promising for HNC MR‐only RT: A comprehensive evaluation of previously developed sCT generation networks. Medical Physics. 2022;49(4):2150-2158. doi:10.1002/mp.15572

2022 doi
[121]

Brain and Head-and-Neck MRI in Immobilization Mask: A Practical Solution for MR-Only Radiotherapy

Mandija S, D’Agata F, Navest RJM, et al. Brain and Head-and-Neck MRI in Immobilization Mask: A Practical Solution for MR-Only Radiotherapy. Front Oncol. 2019;9:647. doi:10.3389/fonc.2019.00647 41

2019
[122]

A pilot study of same-day MRI-only simulation and treatment with MR-guided adaptive palliative radiotherapy (MAP-RT)

Schiff JP, Maraghechi B, Chin RI, et al. A pilot study of same-day MRI-only simulation and treatment with MR-guided adaptive palliative radiotherapy (MAP-RT). Clinical and Translational Radiation Oncology. 2023;39:100561. doi:10.1016/j.ctro.2022.100561

2023
[123]

A Systematic Review of the Clinical Implementation of Pelvic Magnetic Resonance Imaging–Only Planning for External Beam Radiation Therapy

Bird D, Henry AM, Sebag-Montefiore D, Buckley DL, Al-Qaisieh B, Speight R. A Systematic Review of the Clinical Implementation of Pelvic Magnetic Resonance Imaging–Only Planning for External Beam Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 20...

2019 doi
[124]

Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion

Gordon Y, Partovi S, Müller-Eschner M, et al. Dynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusion. Cardiovasc Diagn Ther. 2014;4(2):147-164. doi:10.3978/j.issn.2223- 3652.2014.03.01

2014
[125]

Models and methods for analyzing DCE‐MRI: A review

Khalifa F, Soliman A, El‐Baz A, et al. Models and methods for analyzing DCE‐MRI: A review. Medical Physics. 2014;41(12):124301. doi:10.1118/1.4898202

2014 doi
[126]

Review of dynamic contrast‐enhanced MRI: Technical aspects and applications in the musculoskeletal system

Sujlana P, Skrok J, Fayad LM. Review of dynamic contrast‐enhanced MRI: Technical aspects and applications in the musculoskeletal system. Magnetic Resonance Imaging. 2018;47(4):875-890. doi:10.1002/jmri.25810

2018 doi
[127]

Value of Dynamic Contrast-Enhanced MR Imaging in Diagnosing and Classifying Peripheral Vascular Malformations

Van Rijswijk CSP, Van Der Linden E, Van Der Woude HJ, Van Baalen JM, Bloem JL. Value of Dynamic Contrast-Enhanced MR Imaging in Diagnosing and Classifying Peripheral Vascular Malformations. American Journal of Roentgenology. 2002;178(5):1181-1187. doi:10.2214/ajr.178.5.1781181

2002 doi
[128]

Quantitative Dynamic Contrast-Enhanced MRI Identifies Radiation-Induced Vascular Damage in Patients With Advanced Osteoradionecrosis: Results of a Prospective Study

Mohamed ASR, He R, Ding Y, et al. Quantitative Dynamic Contrast-Enhanced MRI Identifies Radiation-Induced Vascular Damage in Patients With Advanced Osteoradionecrosis: Results of a Prospective Study. International Journal of Radiation Oncology*Biology*Physics. 2020;108(5):1319...

2020 doi
[129]

Glycerol-weighted chemical exchange saturation transfer nanoprobes allow 19F/1H dual-modality magnetic resonance imaging-guided cancer radiotherapy

A R, Wang H, Nie C, et al. Glycerol-weighted chemical exchange saturation transfer nanoprobes allow 19F/1H dual-modality magnetic resonance imaging-guided cancer radiotherapy. Nat Commun. 2023;14(1):6644. doi:10.1038/s41467-023-42286-3

2023 doi
[130]

Magnetic Resonance Imaging of Glucose Uptake and Metabolism in Patients with Head and Neck Cancer

Wang J, Weygand J, Hwang KP, et al. Magnetic Resonance Imaging of Glucose Uptake and Metabolism in Patients with Head and Neck Cancer. Sci Rep. 2016;6(1):30618. doi:10.1038/srep30618

2016 doi
[131]

Liu W, Wang X, Xie S, et al. Amide proton transfer (APT) and magnetization transfer (MT) in predicting short-term therapeutic outcome in nasopharyngeal carcinoma after chemoradiotherapy: a feasibility study of three-dimensional chemical exchange 42 saturation transfer (CEST) M...

2023 doi
[132]

Chemical exchange saturation transfer MRI in central nervous system tumours on a 1.5 T MR-Linac

Chan RW, Lawrence LSP, Oglesby RT, et al. Chemical exchange saturation transfer MRI in central nervous system tumours on a 1.5 T MR-Linac. Radiotherapy and Oncology. 2021;162:140-149. doi:10.1016/j.radonc.2021.07.010

2021 doi
[133]

Semi‐solid MT and APTW CEST‐MRI predict clinical outcome of patients with glioma early after radiotherapy

Kroh F, Von Knebel Doeberitz N, Breitling J, et al. Semi‐solid MT and APTW CEST‐MRI predict clinical outcome of patients with glioma early after radiotherapy. Magnetic Resonance in Med. 2023;90(4):1569-1581. doi:10.1002/mrm.29746

2023 doi
[134]

Evaluation of Glioblastoma Response to Therapy With Chemical Exchange Saturation Transfer

Mehrabian H, Myrehaug S, Soliman H, Sahgal A, Stanisz GJ. Evaluation of Glioblastoma Response to Therapy With Chemical Exchange Saturation Transfer. International Journal of Radiation Oncology*Biology*Physics. 2018;101(3):713-723. doi:10.1016/j.ijrobp.2018.03.057

2018 doi
[135]

Differentiation between Radiation Necrosis and Tumor Progression Using Chemical Exchange Saturation Transfer

Mehrabian H, Desmond KL, Soliman H, Sahgal A, Stanisz GJ. Differentiation between Radiation Necrosis and Tumor Progression Using Chemical Exchange Saturation Transfer. Clinical Cancer Research. 2017;23(14):3667-3675. doi:10.1158/1078-0432.CCR-16-2265

2017 doi
[136]

Chemical Exchange Saturation Transfer MRI for Differentiating Radiation Necrosis From Tumor Progression in Brain Metastasis— Application in a Clinical Setting

Mehrabian H, Chan RW, Sahgal A, et al. Chemical Exchange Saturation Transfer MRI for Differentiating Radiation Necrosis From Tumor Progression in Brain Metastasis— Application in a Clinical Setting. Magnetic Resonance Imaging. 2023;57(6):1713-1725. doi:10.1002/jmri.28440

2023 doi
[137]

CEST imaging of the APT and ssMT predict the overall survival of patients with glioma at the first follow-up after completion of radiotherapy at 3T

Von Knebel Doeberitz N, Kroh F, Breitling J, et al. CEST imaging of the APT and ssMT predict the overall survival of patients with glioma at the first follow-up after completion of radiotherapy at 3T. Radiotherapy and Oncology. 2023;184:109694. doi:10.1016/j.radonc.2023.109694

2023
[138]

Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients

Paech D, Dreher C, Regnery S, et al. Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients. Eur Radiol. 2019;29(9):4957-4967. doi:10.1007/s00330-019-06066-2

2019 doi
[139]

Post-Surgical Depositions of Blood Products Are No Major Confounder for the Diagnostic and Prognostic Performance of CEST MRI in Patients with Glioma

Von Knebel Doeberitz N, Kroh F, König L, et al. Post-Surgical Depositions of Blood Products Are No Major Confounder for the Diagnostic and Prognostic Performance of CEST MRI in Patients with Glioma. Biomedicines. 2023;11(9):2348. doi:10.3390/biomedicines11092348

2023 doi
[140]

Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases

Essed RA, Prysiazhniuk Y, Wamelink IJ, Azizova A, Keil VC. Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases. Eur Radiol. Published online August 12, 2024. doi:10.1007/s00330-024-11004-y 43

2024 doi
[141]

Chemical Exchange Saturation Transfer MRI : Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non‐Small Cell Lung Cancer Patients

Ohno Y, Yui M, Yamamoto K, et al. Chemical Exchange Saturation Transfer MRI : Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non‐Small Cell Lung Cancer Patients. Magnetic Resonance Imaging. 2023;58(1):174-186. doi:10.1002/jmri.28691

2023 doi
[142]

Towards differentiation of brain tumor from radiation necrosis using multi-parametric MRI: Preliminary results at 4.7 T using rodent models

Devan SP, Jiang X, Kang H, et al. Towards differentiation of brain tumor from radiation necrosis using multi-parametric MRI: Preliminary results at 4.7 T using rodent models. Magnetic Resonance Imaging. 2022;94:144-150. doi:10.1016/j.mri.2022.10.002

2022 doi
[143]

Glioblastoma (GBM) effects on quantitative MRI of contralateral normal appearing white matter

Mehrabian H, Lam WW, Myrehaug S, Sahgal A, Stanisz GJ. Glioblastoma (GBM) effects on quantitative MRI of contralateral normal appearing white matter. J Neurooncol. 2018;139(1):97-106. doi:10.1007/s11060-018-2846-0

2018 doi
[144]

Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation

Chan RW, Chen H, Myrehaug S, et al. Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation. J Neurooncol. 2021;151(2):267-278. doi:10.1007/s11060-020-03661-y

2021 doi
[145]

Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients

Regnery S, Adeberg S, Dreher C, et al. Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. Oncotarget. 2018;9(47):28772-28783. doi:10.18632/oncotarget.25594

2018 doi
[146]

Chemical exchange saturation transfer for predicting response to stereotactic radiosurgery in human brain metastasis

Desmond KL, Mehrabian H, Chavez S, et al. Chemical exchange saturation transfer for predicting response to stereotactic radiosurgery in human brain metastasis. Magnetic Resonance in Med. 2017;78(3):1110-1120. doi:10.1002/mrm.26470

2017 doi
[147]

Early response assessment of glioma patients to definitive chemoradiotherapy using chemical exchange saturation transfer imaging at 7 T

Meissner J, Korzowski A, Regnery S, et al. Early response assessment of glioma patients to definitive chemoradiotherapy using chemical exchange saturation transfer imaging at 7 T. Magnetic Resonance Imaging. 2019;50(4):1268-1277. doi:10.1002/jmri.26702

2019 doi
[148]

Artifacts in T1ρ-weighted imaging: Compensation for B1 and B0 field imperfections

Witschey WRT, Borthakur A, Elliott MA, et al. Artifacts in T1ρ-weighted imaging: Compensation for B1 and B0 field imperfections. Journal of Magnetic Resonance. 2007;186(1):75-85. doi:10.1016/j.jmr.2007.01.015

2007 doi
[149]

Differentiation of brain tumor- related edema based on 3D T1rho imaging

Villanueva-Meyer JE, Barajas RF, Mabray MC, et al. Differentiation of brain tumor- related edema based on 3D T1rho imaging. European Journal of Radiology. 2017;91:88-

2017
[150]

Impact of Liver Fibrosis and Fatty Liver on T1rho Measurements: A Prospective Study

Xie S, Li Q, Cheng Y, et al. Impact of Liver Fibrosis and Fatty Liver on T1rho Measurements: A Prospective Study. Korean J Radiol. 2017;18(6):898. doi:10.3348/kjr.2017.18.6.898

2017 doi
[151]

T1ρ for Radiotherapy Treatment Response Monitoring in Rectal Cancer Patients: A Pilot Study

Kooreman ES, Tanaka M, Ter Beek LC, et al. T1ρ for Radiotherapy Treatment Response Monitoring in Rectal Cancer Patients: A Pilot Study. JCM. 2022;11(7):1998. doi:10.3390/jcm11071998 44

2022 doi
[152]

doi:10.1016/j.ejrad.2017.03.022

2017 doi
[153]

The Quality Assurance of a 1.5 T MR-Linac

Riis HL, Chick J, Dunlop A, Tilly D. The Quality Assurance of a 1.5 T MR-Linac. Seminars in Radiation Oncology. 2024;34(1):120-128. doi:10.1016/j.semradonc.2023.10.011

2024 doi
[154]

Recommendations towards standards for quantitative MRI (qMRI) and outstanding needs

Keenan KE, Biller JR, Delfino JG, et al. Recommendations towards standards for quantitative MRI (qMRI) and outstanding needs. Magnetic Resonance Imaging. 2019;49(7). doi:10.1002/jmri.26598

2019 doi
[155]

The QIBA Profile for MRI-based Compositional Imaging of Knee Cartilage

Chalian M, Li X, Guermazi A, et al. The QIBA Profile for MRI-based Compositional Imaging of Knee Cartilage. Radiology. 2021;301(2):423-432. doi:10.1148/radiol.2021204587

2021 doi
[156]

BOLD MRI of human tumor oxygenation during carbogen breathing

Taylor NJ, Baddeley H, Goodchild KA, et al. BOLD MRI of human tumor oxygenation during carbogen breathing. Magnetic Resonance Imaging. 2001;14(2):156-163. doi:10.1002/jmri.1166

2001 doi
[157]

Correlations of noninvasive BOLD and TOLD MRI with pO 2 and relevance to tumor radiation response: Noninvasive BOLD and TOLD MRI of Tumors

Hallac RR, Zhou H, Pidikiti R, et al. Correlations of noninvasive BOLD and TOLD MRI with pO 2 and relevance to tumor radiation response: Noninvasive BOLD and TOLD MRI of Tumors. Magn Reson Med. 2014;71(5):1863-1873. doi:10.1002/mrm.24846

2014 doi
[158]

The Hallmarks of Cancer

Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100(1):57-70. doi:10.1016/S0092-8674(00)81683-9

2000 doi
[159]

Repeatability and sensitivity of measurements in patients with head and neck squamous cell carcinoma at 3T

Panek R, Welsh L, Dunlop A, et al. Repeatability and sensitivity of measurements in patients with head and neck squamous cell carcinoma at 3T. Magnetic Resonance Imaging. 2016;44(1):72-80. doi:10.1002/jmri.25134

2016 doi
[160]

First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer

Dubec MJ, Buckley DL, Berks M, et al. First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer. Radiotherapy and Oncology. 2023;183:109592. doi:10.1016/j.radonc.2023.109592

2023
[161]

Monitoring of Tumor Oxygenation Changes in Head-and-Neck Carcinoma Patients Breathing a Hyperoxic Hypercapnic Gas Mixture with a Noninvasive MRI Technique

Kotas M, Schmitt P, Jakob PM, Flentje M. Monitoring of Tumor Oxygenation Changes in Head-and-Neck Carcinoma Patients Breathing a Hyperoxic Hypercapnic Gas Mixture with a Noninvasive MRI Technique. Strahlenther Onkol. 2009;185(1):19-26. doi:10.1007/s00066-009-1870-6

2009 doi
[162]

Nephrogenic systemic fibrosis and gadolinium-based contrast agents

High WA. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Expert Review of Dermatology. 2007;2(5):593-605. doi:10.1586/17469872.2.5.593 45

2007 doi
[163]

Tissue specific perfusion imaging using arterial spin labeling

Detre JA, Zhang W, Roberts DA, et al. Tissue specific perfusion imaging using arterial spin labeling. NMR in Biomedicine. 1994;7(1-2):75-82. doi:10.1002/nbm.1940070112

1994 doi
[164]

Towards tumour hypoxia imaging: Incorporating relative oxygen extraction fraction mapping of prostate with multi‐ parametric quantitative MRI on a 1

Mesny E, Leporq B, Chapet O, Beuf O. Towards tumour hypoxia imaging: Incorporating relative oxygen extraction fraction mapping of prostate with multi‐ parametric quantitative MRI on a 1. 5T MR ‐linac. J Med Imag Rad Onc. 2024;68(2):171-

2024
[165]

Multidelay pseudocontinuous arterial spin labeling to measure blood flow in the head and neck

Sijtsema ND, Petit SF, Verduijn GM, et al. Multidelay pseudocontinuous arterial spin labeling to measure blood flow in the head and neck. NMR in Biomedicine. 2023;36(7):e4898. doi:10.1002/nbm.4898

2023 doi
[166]

Arterial spin labeling for head and neck lesion assessment: technical adjustments and clinical applications

Martín-Noguerol T, Kirsch CFE, Montesinos P, Luna A. Arterial spin labeling for head and neck lesion assessment: technical adjustments and clinical applications. Neuroradiology. 2021;63(12):1969-1983. doi:10.1007/s00234-021-02772-1

2021 doi
[167]

Histogram analysis of arterial spin labeling perfusion data to determine the human papillomavirus status of oropharyngeal squamous cell carcinomas

Ahn Y, Choi YJ, Sung YS, et al. Histogram analysis of arterial spin labeling perfusion data to determine the human papillomavirus status of oropharyngeal squamous cell carcinomas. Neuroradiology. 2021;63(8):1345-1352. doi:10.1007/s00234-021-02751-6

2021 doi
[168]

A Beginner’s Guide to Arterial Spin Labeling (ASL) Image Processing

Clement P, Petr J, Dijsselhof MBJ, et al. A Beginner’s Guide to Arterial Spin Labeling (ASL) Image Processing. Front Radio. 2022;2:929533. doi:10.3389/fradi.2022.929533

2022
[169]

First demonstration of arterial spin labeling on a 1.5T MR-Linac for characterizing glioblastoma perfusion dynamics

Lawrence LSP, Chugh B, Stewart J, et al. First demonstration of arterial spin labeling on a 1.5T MR-Linac for characterizing glioblastoma perfusion dynamics. In: Vol 0444. ; 2024

2024
[170]

MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders

Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161(2):401-407. doi:10.1148/radiology.161.2.3763909

1986 doi
[171]

Functional evaluation with intravoxel incoherent motion echo‐planar MRI in irradiated salivary glands: A correlative study with salivary gland scintigraphy

Zhang L, Murata Y, Ishida R, Ohashi I, Yoshimura R, Shibuya H. Functional evaluation with intravoxel incoherent motion echo‐planar MRI in irradiated salivary glands: A correlative study with salivary gland scintigraphy. Magnetic Resonance Imaging. 2001;14(3):223-229. doi:10.10...

2001 doi
[172]

Arterial spin labeling to determine tumor viability in head and neck cancer before and after treatment

Fujima N, Kudo K, Yoshida D, et al. Arterial spin labeling to determine tumor viability in head and neck cancer before and after treatment. Magnetic Resonance Imaging. 2014;40(4):920-928. doi:10.1002/jmri.24421

2014 doi
[173]

Head and Neck Tumors: Assessment of Perfusion-Related Parameters and Diffusion Coefficients Based on the Intravoxel Incoherent Motion Model

Sumi M, Nakamura T. Head and Neck Tumors: Assessment of Perfusion-Related Parameters and Diffusion Coefficients Based on the Intravoxel Incoherent Motion Model. AJNR Am J Neuroradiol. 2013;34(2):410-416. doi:10.3174/ajnr.A3227 46

2013 doi
[174]

Characterization and therapy monitoring of head and neck carcinomas using diffusion-imaging-based intravoxel incoherent motion parameters—preliminary results

Hauser T, Essig M, Jensen A, et al. Characterization and therapy monitoring of head and neck carcinomas using diffusion-imaging-based intravoxel incoherent motion parameters—preliminary results. Neuroradiology. 2013;55(5):527-536. doi:10.1007/s00234-013-1154-9

2013 doi
[175]

Prediction of treatment response in head and neck carcinomas using IVIM-DWI: Evaluation of lymph node metastasis

Hauser T, Essig M, Jensen A, et al. Prediction of treatment response in head and neck carcinomas using IVIM-DWI: Evaluation of lymph node metastasis. European Journal of Radiology. 2014;83(5):783-787. doi:10.1016/j.ejrad.2014.02.013

2014 doi
[176]

doi:10.1111/1754-9485.13626
[177]

Simple and Reliable Determination of Intravoxel Incoherent Motion Parameters for the Differential Diagnosis of Head and Neck Tumors

Sasaki M, Sumi M, Eida S, Katayama I, Hotokezaka Y, Nakamura T. Simple and Reliable Determination of Intravoxel Incoherent Motion Parameters for the Differential Diagnosis of Head and Neck Tumors. Jespersen SN, ed. PLoS ONE. 2014;9(11):e112866. doi:10.1371/journal.pone.0112866

2014 doi
[178]

Longitudinal Correlations Between Intravoxel Incoherent Motion (IVIM) and Dynamic Contrast-Enhanced (DCE) MRI During Radiotherapy in Prostate Cancer Patients

Kooreman ES, Van Pelt V, Nowee ME, Pos F, Van Der Heide UA, Van Houdt PJ. Longitudinal Correlations Between Intravoxel Incoherent Motion (IVIM) and Dynamic Contrast-Enhanced (DCE) MRI During Radiotherapy in Prostate Cancer Patients. Front Oncol. 2022;12:897130. doi:10.3389/fon...

2022
[179]

An optimal acquisition and post‐processing pipeline for hybrid IVIM‐DKI in head and neck

Sijtsema ND, Petit SF, Poot DHJ, et al. An optimal acquisition and post‐processing pipeline for hybrid IVIM‐DKI in head and neck. Magnetic Resonance in Med. 2021;85(2):777-789. doi:10.1002/mrm.28461

2021 doi
[180]

Ding Y, Hazle JD, Mohamed ASR, et al. Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study: IVIM Kinetics during Chemoradiotherap...

2015 doi
[181]

Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study

Kooreman ES, van Houdt PJ, Keesman R, et al. Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study. Front Oncol. 2021;11. doi:10.3389/fonc.2021.705964

2021
[182]

Rapid magnetic resonance quantification on the brain: Optimization for clinical usage

Warntjes JBM, Leinhard OD, West J, Lundberg P. Rapid magnetic resonance quantification on the brain: Optimization for clinical usage. Magnetic Resonance in Med. 2008;60(2):320-329. doi:10.1002/mrm.21635

2008 doi
[183]

3D T2-weighted fast spin- echo MRI sialography of the parotid gland

Sartoretti-Schefer S, Kollias S, Wichmann W, Valavanis A. 3D T2-weighted fast spin- echo MRI sialography of the parotid gland. Neuroradiology. 1999;41(1):46-51. doi:10.1007/s002340050704 47

1999 doi
[184]

Multiparametric magnetic resonance imaging in mucosal primary head and neck cancer: a prospective imaging biomarker study

Rumley CN, Lee MT, Holloway L, et al. Multiparametric magnetic resonance imaging in mucosal primary head and neck cancer: a prospective imaging biomarker study. BMC Cancer. 2017;17(1):475. doi:10.1186/s12885-017-3448-5

2017 doi
[185]

Changes in serial multiparametric MRI and FDG- PET/CT functional imaging during radiation therapy can predict treatment response in patients with head and neck cancer

Trada Y, Keall P, Jameson M, et al. Changes in serial multiparametric MRI and FDG- PET/CT functional imaging during radiation therapy can predict treatment response in patients with head and neck cancer. Eur Radiol. 2023;33(12):8788-8799. doi:10.1007/s00330-023-09843-2

2023 doi
[186]

Simultaneous three-dimensional myocardial T1 and T2 mapping in one breath hold with 3D-QALAS

Kvernby S, Warntjes MJB, Haraldsson H, Carlhäll CJ, Engvall J, Ebbers T. Simultaneous three-dimensional myocardial T1 and T2 mapping in one breath hold with 3D-QALAS. Journal of Cardiovascular Magnetic Resonance. 2014;16(1):102. doi:10.1186/s12968-014-0102-0

2014 doi
[187]

Three-dimensional high-resolution simultaneous quantitative mapping of the whole brain with 3D-QALAS: An accuracy and repeatability study

Fujita S, Hagiwara A, Hori M, et al. Three-dimensional high-resolution simultaneous quantitative mapping of the whole brain with 3D-QALAS: An accuracy and repeatability study. Magnetic Resonance Imaging. 2019;63:235-243. doi:10.1016/j.mri.2019.08.031

2019 doi
[188]

Hagiwara A, Hori M, Cohen-Adad J, et al. Linearity, Bias, Intrascanner Repeatability, and Interscanner Reproducibility of Quantitative Multidynamic Multiecho Sequence for Rapid Simultaneous Relaxometry at 3 T: A Validation Study With a Standardized Phantom and Healthy Controls...

2019 doi
[189]

SyMRI of the Brain: Rapid Quantification of Relaxation Rates and Proton Density, With Synthetic MRI, Automatic Brain Segmentation, and Myelin Measurement

Hagiwara A, Warntjes M, Hori M, et al. SyMRI of the Brain: Rapid Quantification of Relaxation Rates and Proton Density, With Synthetic MRI, Automatic Brain Segmentation, and Myelin Measurement. Invest Radiol. 2017;52(10):647-657. doi:10.1097/RLI.0000000000000365

2017 doi
[190]

Investigation of synthetic MRI with quantitative parameters for discriminating axillary lymph nodes status in invasive breast cancer

Qu M, Feng W, Liu X, et al. Investigation of synthetic MRI with quantitative parameters for discriminating axillary lymph nodes status in invasive breast cancer. European Journal of Radiology. 2024;175:111452. doi:10.1016/j.ejrad.2024.111452

2024
[191]

Histogram analysis of MR quantitative parameters: are they correlated with prognostic factors in prostate cancer? Abdom Radiol

Chen Y, Meng T, Cao W, et al. Histogram analysis of MR quantitative parameters: are they correlated with prognostic factors in prostate cancer? Abdom Radiol. 2024;49(5):1534-1544. doi:10.1007/s00261-024-04227-6

2024 doi
[192]

Cross-vendor multiparametric mapping of the human brain using 3D-QALAS: A multicenter and multivendor study

Fujita S, Gagoski B, Hwang KP, et al. Cross-vendor multiparametric mapping of the human brain using 3D-QALAS: A multicenter and multivendor study. Magnetic Resonance in Medicine. 2024;91(5):1863-1875. doi:10.1002/mrm.29939

2024 doi
[193]

Synthetic MR: Physical principles, clinical implementation, and new developments

Hwang K, Fujita S. Synthetic MR: Physical principles, clinical implementation, and new developments. Medical Physics. 2022;49(7):4861-4874. doi:10.1002/mp.15686

2022 doi
[194]

Synthetic MRI and diffusion-weighted imaging for differentiating nasopharyngeal lymphoma from nasopharyngeal carcinoma: combination with morphological features

Zhang H, Hu L, Qin F, et al. Synthetic MRI and diffusion-weighted imaging for differentiating nasopharyngeal lymphoma from nasopharyngeal carcinoma: combination with morphological features. British Journal of Radiology. 2024;97(1159):1278-1285. doi:10.1093/bjr/tqae095

2024 doi
[195]

Qualitative and Quantitative Performance of Magnetic Resonance Image Compilation (MAGiC) Method: An Exploratory Analysis for Head and Neck Imaging

Konar AS, Paudyal R, Shah AD, et al. Qualitative and Quantitative Performance of Magnetic Resonance Image Compilation (MAGiC) Method: An Exploratory Analysis for Head and Neck Imaging. Cancers. 2022;14(15):3624. doi:10.3390/cancers14153624

2022 doi
[196]

A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple- Negative Breast Cancer

Hwang KP, Elshafeey NA, Kotrotsou A, et al. A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple- Negative Breast Cancer. Radiology: Imaging Cancer. 2023;5(4):e230009. doi:10.1148/rycan.230009

2023 doi
[197]

Radiation-dependent demyelination in normal appearing white matter in glioma patients, determined using quantitative magnetic resonance imaging

Ljusberg A, Blystad I, Lundberg P, Adolfsson E, Tisell A. Radiation-dependent demyelination in normal appearing white matter in glioma patients, determined using quantitative magnetic resonance imaging. Physics and Imaging in Radiation Oncology. 2023;27:100451. doi:10.1016/j.p...

2023
[198]

A method for sensitivity analysis of automatic contouring algorithms across different contrast weightings using synthetic magnetic resonance imaging

McCullum L, Belal Z, Floyd W, et al. A method for sensitivity analysis of automatic contouring algorithms across different contrast weightings using synthetic magnetic resonance imaging. Physics and Imaging in Radiation Oncology. 2025;35:100790. doi:10.1016/j.phro.2025.100790

2025
[199]

Magnetic resonance fingerprinting

Ma D, Gulani V, Seiberlich N, et al. Magnetic resonance fingerprinting. Nature. 2013;495(7440):187-192. doi:10.1038/nature11971

2013 doi
[200]

Technical development and In Silico implementation of SyntheticMR in head and neck adaptive radiation therapy: A prospective R‐IDEAL stage 0/1 technology development report

McCullum L, Mulder SL, West NA, et al. Technical development and In Silico implementation of SyntheticMR in head and neck adaptive radiation therapy: A prospective R‐IDEAL stage 0/1 technology development report. J Applied Clin Med Phys. 2025;26(7):e70134. doi:10.1002/acm2.70134

2025 doi
[201]

Technical Optimization of SyntheticMR for the Head and Neck on a 3T MR-Simulator and 1.5T MR-Linac: A Prospective R-IDEAL Stage 2a Technology Innovation Report

McCullum L, Mulder SL, West NA, et al. Technical Optimization of SyntheticMR for the Head and Neck on a 3T MR-Simulator and 1.5T MR-Linac: A Prospective R-IDEAL Stage 2a Technology Innovation Report. Published online April 10, 2025. doi:10.1101/2025.04.08.25325491

2025 doi
[202]

3D magnetic resonance fingerprinting for rapid simultaneous T1, T2, and T1ρ volumetric mapping of human articular cartilage at 3 T

Sharafi A, Zibetti MVW, Chang G, Cloos M, Regatte RR. 3D magnetic resonance fingerprinting for rapid simultaneous T1, T2, and T1ρ volumetric mapping of human articular cartilage at 3 T. NMR in Biomedicine. 2022;35(12):e4800. doi:10.1002/nbm.4800

2022 doi
[203]

Rapid and quantitative chemical exchange saturation transfer (CEST) imaging with magnetic resonance 49 fingerprinting (MRF)

Cohen O, Huang S, McMahon MT, Rosen MS, Farrar CT. Rapid and quantitative chemical exchange saturation transfer (CEST) imaging with magnetic resonance 49 fingerprinting (MRF). Magnetic Resonance in Med. 2018;80(6):2449-2463. doi:10.1002/mrm.27221

2018 doi
[204]

Feasibility of 3D MRI fingerprinting for rapid knee cartilage T 1 , T 2, and T 1ρ mapping at 0.55T: Comparison with 3T

De Moura HL, Monga A, Zhang X, Zibetti MVW, Keerthivasan MB, Regatte RR. Feasibility of 3D MRI fingerprinting for rapid knee cartilage T 1 , T 2, and T 1ρ mapping at 0.55T: Comparison with 3T. NMR in Biomedicine. Published online August 21, 2024:e5250. doi:10.1002/nbm.5250

2024 doi
[205]

AGE‐DEPENDENT CHANGES in KNEE CARTILAGE T 1 , T 2 , AND T 1 P SIMULTANEOUSLY MEASURED USING MRI FINGERPRINTING

Kijowski R, Sharafi A, Zibetti MVW, Chang G, Cloos MA, Regatte RR. AGE‐DEPENDENT CHANGES in KNEE CARTILAGE T 1 , T 2 , AND T 1 P SIMULTANEOUSLY MEASURED USING MRI FINGERPRINTING. Magnetic Resonance Imaging. 2023;57(6):1805-1812. doi:10.1002/jmri.28451

2023 doi
[206]

Technical overview of magnetic resonance fingerprinting and its applications in radiation therapy

Chen Y, Lu L, Zhu T, Ma D. Technical overview of magnetic resonance fingerprinting and its applications in radiation therapy. Medical Physics. 2022;49(4):2846-2860. doi:10.1002/mp.15254

2022 doi
[207]

Toward magnetic resonance fingerprinting for low‐field MR‐guided radiation therapy

Mickevicius NJ, Kim JP, Zhao J, Morris ZS, Hurst NJ, Glide‐Hurst CK. Toward magnetic resonance fingerprinting for low‐field MR‐guided radiation therapy. Medical Physics. 2021;48(11):6930-6940. doi:10.1002/mp.15202

2021 doi
[208]

CEST MR fingerprinting (CEST‐MRF) for brain tumor quantification using EPI readout and deep learning reconstruction

Cohen O, Yu VY, Tringale KR, et al. CEST MR fingerprinting (CEST‐MRF) for brain tumor quantification using EPI readout and deep learning reconstruction. Magnetic Resonance in Med. 2023;89(1):233-249. doi:10.1002/mrm.29448

2023 doi
[209]

Simultaneous perfusion, diffusion, T 2 *, and T 1 mapping with MR fingerprinting

Fan H, Bunker L, Wang Z, et al. Simultaneous perfusion, diffusion, T 2 *, and T 1 mapping with MR fingerprinting. Magnetic Resonance in Med. 2024;91(2):558-569. doi:10.1002/mrm.29880

2024 doi
[210]

Respiratory-Correlated 4-Dimensional Magnetic Resonance Fingerprinting for Liver Cancer Radiation Therapy Motion Management

Liu C, Li T, Cao P, et al. Respiratory-Correlated 4-Dimensional Magnetic Resonance Fingerprinting for Liver Cancer Radiation Therapy Motion Management. International Journal of Radiation Oncology*Biology*Physics. 2023;117(2):493-504. doi:10.1016/j.ijrobp.2023.04.015

2023 doi
[211]

Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation

Heukelom J, Kantor ME, Mohamed ASR, et al. Differences between planned and delivered dose for head and neck cancer, and their consequences for normal tissue complication probability and treatment adaptation. Radiotherapy and Oncology. 2020;142:100-106. doi:10.1016/j.radonc.2019.07.034

2020 doi
[212]

LOW‐RANK inversion reconstruction for THROUGH‐ PLANE accelerated radial MR fingerprinting applied to relaxometry at 0

Mickevicius NJ, Glide‐Hurst CK. LOW‐RANK inversion reconstruction for THROUGH‐ PLANE accelerated radial MR fingerprinting applied to relaxometry at 0. 35 T. Magnetic Resonance in Med. 2022;88(2):840-848. doi:10.1002/mrm.29244

2022 doi
[213]

Technical feasibility of magnetic resonance fingerprinting on a 1.5T MRI-linac

Bruijnen T, Van Der Heide O, Intven MPW, et al. Technical feasibility of magnetic resonance fingerprinting on a 1.5T MRI-linac. Phys Med Biol. 2020;65(22):22NT01. doi:10.1088/1361-6560/abbb9d

2020 doi
[214]

Markov models for clinical decision‐making in radiation oncology: A systematic review

McCullum LB, Karagoz A, Dede C, et al. Markov models for clinical decision‐making in radiation oncology: A systematic review. J Med Imag Rad Onc. Published online May 20, 2024:1754-9485.13656. doi:10.1111/1754-9485.13656

2024
[215]

Hosseinian S, Hemmati M, Dede C, et al. Cluster-Based Toxicity Estimation of Osteoradionecrosis Via Unsupervised Machine Learning: Moving Beyond Single Dose- Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification. ...

2024 doi
[216]

Optimal timing of re- planning for head and neck adaptive radiotherapy

Gan Y, Langendijk JA, Oldehinkel E, Lin Z, Both S, Brouwer CL. Optimal timing of re- planning for head and neck adaptive radiotherapy. Radiotherapy and Oncology. 2024;194:110145. doi:10.1016/j.radonc.2024.110145

2024
[217]

Nosrat F, Dede C, McCullum LB, et al. Personalized Rescheduling of Adaptive Organ-at-Risk-Sparing Radiation Therapy for Head and Neck Cancer under Re-planning Resource Constraints: A Novel Application of Markov Decision Processes. Published online April 2, 2024. doi:10.1101/20...

2024 doi
[218]

Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation

Stahlberg EA, Abdel-Rahman M, Aguilar B, et al. Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation. Front Digit Health. 2022;4:1007784. doi:10.3389/fdgth.2022.1007784

2022
[219]

Digital Twins for Radiation Oncology

Jensen J, Deng J. Digital Twins for Radiation Oncology. In: Companion Proceedings of the ACM Web Conference 2023. ACM; 2023:989-993. doi:10.1145/3543873.3587688

2023
[220]

Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model

Ng SP, Ajayi T, Schaefer AJ, et al. Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. Cancer. 2020;126(4):749-756. doi:10.1002/cncr.32597

2020 doi
[221]

Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy

Ng SP, Pollard C, Berends J, et al. Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer. 2019;125(11):1823-1829. doi:10.1002/cncr.31983

2019 doi
[222]

A Review of Intelligent Subway Tunnels Based on Digital Twin Technology

Zhao Y, Liu Y, Mu E. A Review of Intelligent Subway Tunnels Based on Digital Twin Technology. Buildings. 2024;14(8):2452. doi:10.3390/buildings14082452

2024 doi
[223]

Utilizing Artificial Intelligence for Head and Neck Cancer Outcomes Prediction From Imaging

Chinnery T, Arifin A, Tay KY, et al. Utilizing Artificial Intelligence for Head and Neck Cancer Outcomes Prediction From Imaging. Can Assoc Radiol J. 2021;72(1):73-85. doi:10.1177/0846537120942134

2021 doi
[224]

Adaptive radiotherapy for head and neck cancer

Morgan HE, Sher DJ. Adaptive radiotherapy for head and neck cancer. Cancers Head Neck. 2020;5(1):1. doi:10.1186/s41199-019-0046-z

2020 doi
[225]

Adaptive radiation therapy for head and neck cancer

Juloori A, Ward MC, Joshi NP, et al. Adaptive radiation therapy for head and neck cancer. ARO. Published online September 1, 2015:12-17. doi:10.37549/ARO1073

2015 doi
[228]

Keall PJ, Nguyen DT, O’Brien R, et al. Review of Real-Time 3-Dimensional Image Guided Radiation Therapy on Standard-Equipped Cancer Radiation Therapy Systems: Are We at the Tipping Point for the Era of Real-Time Radiation Therapy? International Journal of Radiation Oncology*Bi...

2018 doi
[479]

doi:10.1111/j.1442-2050.2009.01037.x

2009
[642]

doi:10.1002/mp.13927

doi

Pith tools

Reviewed August 6, 2026 · model on record in the stance chip above.

[1] [1]

Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist’s point of view

Nuyts S, Bollen H, Eisbruch A, et al. Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist’s point of view. Cancer Medicine. 2024;13(8):e7192. doi:10.1002/cam4.7192

work page doi:10.1002/cam4.7192 2024

[2] [2]

Clinical and dosimetric impact of adaptive intensity-modulated radiotherapy in locally advanced head-and- neck cancer

Maheshwari G, Dhanawat A, Kumar HS, Sharma N, Jakhar SL. Clinical and dosimetric impact of adaptive intensity-modulated radiotherapy in locally advanced head-and- neck cancer. Journal of Cancer Research and Therapeutics. 2020;16(3):600-604. doi:10.4103/jcrt.JCRT_928_19

work page doi:10.4103/jcrt.jcrt_928_19 2020

[3] [3]

In silico evaluation and feasibility of near margin- less head and neck daily adaptive radiotherapy

Dohopolski M, Visak J, Choi B, et al. In silico evaluation and feasibility of near margin- less head and neck daily adaptive radiotherapy. Radiotherapy and Oncology. 2024;197:110178. doi:10.1016/j.radonc.2024.110178

arXiv 2024

[4] [4]

In Silico Analysis of Adjuvant Head and Neck Online Adaptive Radiation Therapy

All S, Zhong X, Choi B, et al. In Silico Analysis of Adjuvant Head and Neck Online Adaptive Radiation Therapy. Advances in Radiation Oncology. 2024;9(1):101319. doi:10.1016/j.adro.2023.101319

arXiv 2024

[5] [5]

Replanning During Intensity Modulated Radiation Therapy Improved Quality of Life in Patients With Nasopharyngeal Carcinoma

Yang H, Hu W, Wang W, Chen P, Ding W, Luo W. Replanning During Intensity Modulated Radiation Therapy Improved Quality of Life in Patients With Nasopharyngeal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 2013;85(1):e47-e54. doi:10.1016/j.ijrobp.2012.09.033

work page doi:10.1016/j.ijrobp.2012.09.033 2013

[6] [6]

The Levels of Evidence and Their Role in Evidence- Based Medicine: Plastic and Reconstructive Surgery

Burns PB, Rohrich RJ, Chung KC. The Levels of Evidence and Their Role in Evidence- Based Medicine: Plastic and Reconstructive Surgery. 2011;128(1):305-310. doi:10.1097/PRS.0b013e318219c171

work page doi:10.1097/prs.0b013e318219c171 2011

[7] [7]

Disease Control and Late Toxicity in Adaptive Dose Painting by Numbers Versus Nonadaptive Radiation Therapy for Head and Neck Cancer: A Randomized Controlled Phase 2 Trial

De Bruycker A, De Neve W, Daisne JF, et al. Disease Control and Late Toxicity in Adaptive Dose Painting by Numbers Versus Nonadaptive Radiation Therapy for Head and Neck Cancer: A Randomized Controlled Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 2024;120(2):516-527. doi:10.1016/j.ijrobp.2024.01.012 30

work page doi:10.1016/j.ijrobp.2024.01.012 2024

[8] [8]

Adaptive Dose Painting by Numbers for Head-and-Neck Cancer

Duprez F, De Neve W, De Gersem W, Coghe M, Madani I. Adaptive Dose Painting by Numbers for Head-and-Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 2011;80(4):1045-1055. doi:10.1016/j.ijrobp.2010.03.028

work page doi:10.1016/j.ijrobp.2010.03.028 2011